Tumor-related molecular mechanisms of oxaliplatin resistance E Martinez-Balibrea, A Martínez-Cardús, A Ginés, V Ruiz de Porras, ... Molecular cancer therapeutics 14 (8), 1767-1776, 2015 | 294 | 2015 |
Resistant mechanisms to BRAF inhibitors in melanoma JL Manzano, L Layos, C Bugés, M de los Llanos Gil, L Vila, ... Annals of translational medicine 4 (12), 2016 | 275 | 2016 |
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis D Rosmarin, C Palles, D Church, E Domingo, A Jones, E Johnstone, ... Journal of Clinical Oncology 32 (10), 1031, 2014 | 262 | 2014 |
ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and … M Yin, J Yan, E Martinez-Balibrea, F Graziano, HJ Lenz, HJ Kim, J Robert, ... Clinical cancer research 17 (6), 1632-1640, 2011 | 195 | 2011 |
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy E Martinez-Balibrea, A Abad, A Martínez-Cardús, A Ginés, M Valladares, ... British journal of cancer 103 (4), 581-589, 2010 | 131 | 2010 |
Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway V Ruiz de Porras, S Bystrup, A Martínez-Cardús, R Pluvinet, L Sumoy, ... Scientific reports 6 (1), 24675, 2016 | 124 | 2016 |
CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer S Cabrero-de Las Heras, E Martínez-Balibrea World journal of gastroenterology 24 (42), 4738, 2018 | 115 | 2018 |
Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer C Moutinho, A Martinez-Cardús, C Santos, V Navarro-Pérez, ... Journal of the national cancer institute 106 (1), djt322, 2014 | 109 | 2014 |
A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect P Lopez-Serra, M Marcilla, A Villanueva, A Ramos-Fernandez, A Palau, ... Nature communications 5 (1), 3608, 2014 | 107 | 2014 |
Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer E Martinez-Balibrea, A Abad, E Aranda, J Sastre, JL Manzano, ... European Journal of Cancer 44 (9), 1229-1237, 2008 | 97 | 2008 |
Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells C Plasencia, E Martinez-Balibrea, A Martinez-Cardus, DI Quinn, A Abad, ... International journal of oncology 29 (1), 225-235, 2006 | 86 | 2006 |
Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1 … RR Font A1, Sánchez JM, Tarón M, Martinez-Balibrea E, Sánchez JJ, Manzano JL ... Investigational new drugs 21 (4), 435-443, 2003 | 85 | 2003 |
Hypoxia: the cornerstone of glioblastoma M Domènech, A Hernández, A Plaja, E Martínez-Balibrea, C Balañà International journal of molecular sciences 22 (22), 12608, 2021 | 84 | 2021 |
A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines E Martinez-Balibrea, C Plasencia, A Ginés, A Martinez-Cardús, ... Molecular cancer therapeutics 8 (4), 771-778, 2009 | 83 | 2009 |
Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin‐based chemotherapy E Martinez‐Balibrea, A Martínez‐Cardús, E Musulén, A Ginés, ... International journal of cancer 124 (12), 2905-2910, 2009 | 82 | 2009 |
Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer A Martinez-Cardus, E Martinez-Balibrea, E Bandres, R Malumbres, ... Molecular cancer therapeutics 8 (1), 194-202, 2009 | 76 | 2009 |
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer J Codony-Servat, M Cuatrecasas, E Asensio, C Montironi, ... British journal of cancer 117 (12), 1777-1786, 2017 | 65 | 2017 |
Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells S Gonçalves-Ribeiro, NG Díaz-Maroto, M Berdiel-Acer, A Soriano, ... Oncotarget 7 (37), 59766, 2016 | 54 | 2016 |
Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic … E Martinez-Balibrea, JL Manzano, A Martinez-Cardus, T Moran, ... Oncology reports 17 (3), 637-645, 2007 | 47 | 2007 |
The effect of the UGT1A1* 28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis MM Dias, JP Pignon, CS Karapetis, V Boige, B Glimelius, DM Kweekel, ... The pharmacogenomics journal 14 (5), 424-431, 2014 | 45 | 2014 |